

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
22 November 2007 (22.11.2007)

PCT

(10) International Publication Number
WO 2007/132307 A1

(51) International Patent Classification:

C07D 413/04 (2006.01) A61P 9/00 (2006.01)
C07D 271/06 (2006.01) A61P 17/00 (2006.01)
C07D 213/38 (2006.01) A61P 19/00 (2006.01)
C07D 401/04 (2006.01) A61P 25/00 (2006.01)
C07D 417/04 (2006.01) A61K 31/4245 (2006.01)
C07D 271/10 (2006.01) A61K 31/4439 (2006.01)
A61P 35/00 (2006.01) A61K 31/506 (2006.01)

(US). **MAGUIRE, Robert, John** [GB/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340 (US).

(74) Agents: **FULLER, Grover, F., Jr.** et al.; Pfizer Inc., 150 East 42nd Street, New York, NY 10017 (US).

(21) International Application Number:

PCT/IB2007/001125

(22) International Filing Date: 26 April 2007 (26.04.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/799,211 9 May 2006 (09.05.2006) US

(71) Applicant (for all designated States except US): **PFIZER PRODUCTS INC.** [US/US]; Eastern Point Road, Groton, CT 06340 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BHAT-TACHARYA, Samit, Kumar** [IN/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340 (US). **BROWN, Matthew, Frank** [US/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340 (US). **DORFF, Peter, Hans** [US/US]; Pfizer Global Research & Development, Eastern Point Road, Groton, CT 06340 (US). **LA GRECA, Susan, Deborah** [US/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CYCLOALKYLAMINO ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF



(57) Abstract: The invention relates to compounds of formula (I) and to pharmaceutically acceptable salts, prodrugs, solvates or hydrates thereof; wherein B, D, E, R¹, R², R³, R⁴, R⁵, R⁸, m, n, p, q, r, s, t and u are as defined herein. This invention also relates to a method of using such compounds in the treatment of hyperproliferative diseases and autoimmune diseases in mammals, especially humans, and to pharmaceutical compositions containing such compounds.